By analyzing the relationship between CDK1 expression and tumor-infiltrating lymphocytes (TILs) [33], researchers can more accurately predict patients’ responses to immunotherapy, thus achieving more accurate individualized immunotherapy. The gene discussed is CDK1; the disease is neoplasm.